Biopharmaceutical approval trends in 2009

BioPharm International

Volumn 23, Issue 10, 2010, Pages 30-41

  Walsh, Gary ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIDIABETIC AGENT; ARZERRA; BIOPIN; CANAKINUMAB; CATUMAXOMAB; CERTOLIZUMAB PEGOL; ECALLANTIDE; EPOETIN THETA; EPORATIO; ETANERCEPT; FERTIVID; FILGRASTIM HEXAL; GOLIMUMAB; INFLIXIMAB; KALBITOR; LIRAGLUTIDE; METHOTREXATE; MONOCLONAL ANTIBODY; OFATUMUMAB; OPGENRA; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PROTEIN; REMOVAB; RILONACEPT; SIMPONI; TOCILIZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; ZARZIO;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ARTICLE; ASCITES TUMOR; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BIOTECHNOLOGY; BLOOD CLOTTING; BONE GRAFT; CANCER PREVENTION; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CINCA SYNDROME; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FEMALE INFERTILITY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION SYSTEM; GENETIC DISORDER; HEADACHE; HUMAN; HYPOGLYCEMIA; INFECTION; INFERTILITY; INFLAMMATION; LYMPHOCYTOPENIA; MUCKLE WELLS SYNDROME; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; PATENT; PHARMACEUTICS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPERMATOGENESIS; SPINE FUSION; SPONDYLOLISTHESIS; THROMBOCYTOPENIA; TREND STUDY; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 78650325808     PISSN: 1542166X     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (7)

1. The future of the biological market. Business insights report. 2010 Mar. Available from: www.globalbusinessinsights.com
2. Carlson B. Biosimilar market fails to meet projections. Gen Eng Biotechnol News. 2009;29:43-5.
3. US Food and Drug Administration. CDER drug and biologic calendar year approvals. 2009 Dec. 31. Available from: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ DrugandBiologicApprovalReports/PriorityNDAandBLAApprovals/UCM090995.pdf4.
4. European Medicines Agency. Available from: http://www.ema.europa.eu/ema.
5. Walsh G. Biopharmaceuticals: approvals and approval trends in 2008. Biopharm Int. 2009;22(10):68-77.
6. Walsh G. Biopharmaceuticals: approval trends in 2007. BioPharm Int. 2008;21(10):52-65.
7. Walsh G. Biopharmaceuticals: approval trends in 2006. BioPharm Int. 2007;20(10):56-67.